ABLYNX (OTCMKTS:ABLYF) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other research analysts have also weighed in on ABLYF. Zacks Investment Research raised ABLYNX from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Wednesday, January 17th. Bank of America began coverage on ABLYNX in a research note on Friday, November 10th. They set a “buy” rating and a $26.00 price target on the stock.

ABLYNX (OTCMKTS:ABLYF) opened at $54.40 on Friday. ABLYNX has a 52 week low of $11.10 and a 52 week high of $54.75.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/ablynx-ablyf-upgraded-to-hold-by-valuengine/1843105.html.

ABLYNX Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.